1223P Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)

S Popat,H.A Jung,S Yup Lee,M.J Hochmair,S.H Lee,C Escriu,M.K Lee,M.R Migliorino,Y.C Lee,N Girard,H Daoud,A Märten,S Miura

doi:10.1016/j.annonc.2021.08.1828

1223P Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)

S Popat, H.A Jung + Show 11 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.1828

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2021
Citations: 1	License type: publisher-specific-oa

Affiliation: Chonbuk National University Hospital, Kyungpook National University, Pusan National University, Kyung Hee University, Boehringer Ingelheim (Germany), Niigata Cancer Center Hospital, Clatterbridge Cancer Centre NHS Foundation Trust, Institute of Cancer Research, National Health Service, Institut du Thorax, Institute Curie

#EGFR TKIs #Optimal Sequence Of Treatment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

While 2nd- and 3rd-gen EGFR TKIs have shown clinical benefit vs 1st-gen EGFR TKIs in pts with EGFRm+ NSCLC, optimal sequence of treatment (tx) has yet to be defined. Overall survival (OS) is influenced by the availability/use of subsequent therapy after 1st-line tx. Emergence of T790M is the main mechanism of resistance to 2nd-gen EGFR TKIs and 2nd-line osi could be a tx option in this instance. A previous study (GioTag) showed median OS of >3 yrs in T790M+ pts treated with sequential afa/osi.

Full Text